Haseeb Ahmad – Country President, Novartis UK
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Address: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Camberley, Surrey, GU16 7SR, United Kingdom
Tel: +44 (0)1276 692255
Web: http://www.novartis.co.uk/index.shtml
Novartis UK is the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world. This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz.
Headquartered in Basel, Novartis employs nearly 100,000 people worldwide and has a presence in over 140 countries. Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies – particularly in oncology, transplantation and ophthalmology. The company is also known for producing new and ever-more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
Novartis currently has a total of 145 development projects in various stages of clinical development, including potential new products and potential new indications or formulations for existing products.
x Cardiovascular and Metabolism
x Hypertension, Diabetes, Atherosclerosis
x Integrated Speciality Medicines
x Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergies
x Infectious diseases, Transplantation and Immunology
x Organ transplants
x Neuroscience
x Alzheimer’s, Parkinson’s, Epilepsy, Multiple sclerosis
x Ophthalmics
x Age-related macular degeneration, Dry eye Haematologic and solid tumour diseases
Novartis Oncology aims to improve and extend the lives of patients with cancer. It has a wide range of therapy areas, and a broad pipeline of new products and new indications.
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to…
Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in…
See our Cookie Privacy Policy Here
